Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention.

[1]  P. Gurbel,et al.  The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. , 2009, American heart journal.

[2]  B. Gersh,et al.  Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. , 2009, Journal of the American College of Cardiology.

[3]  R. Ferrari,et al.  Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention: Results From the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance , 2009, Circulation.

[4]  P. Morange,et al.  Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. , 2008, JACC. Cardiovascular interventions.

[5]  E. Antman,et al.  Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38 , 2008, Circulation.

[6]  G. Patti,et al.  Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. , 2008, Journal of the American College of Cardiology.

[7]  E. Mahmud,et al.  Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. , 2008, Journal of the American College of Cardiology.

[8]  S. Goto,et al.  A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. , 2008, European heart journal.

[9]  P. Barragan,et al.  Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. , 2008, Journal of the American College of Cardiology.

[10]  J. Alpert,et al.  Universal definition of myocardial infarction. , 2007, European heart journal.

[11]  C. Macaya,et al.  Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. , 2007, Journal of the American College of Cardiology.

[12]  Jeroen J. Bax,et al.  Universal definition of myocardial infarction. , 2007 .

[13]  D. Angiolillo,et al.  Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study , 2007, Circulation.

[14]  D. Atar,et al.  Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. , 2007, Thrombosis research.

[15]  C. Macaya,et al.  Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. , 2006, Journal of the American College of Cardiology.

[16]  V. Serebruany,et al.  Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. , 2006, Methods and findings in experimental and clinical pharmacology.

[17]  J. Akkerman,et al.  Platelet Inhibition by Insulin Is Absent in Type 2 Diabetes Mellitus , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[18]  D. Cutlip,et al.  Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Cardiac enzyme elevation after successful percutaneous coronary intervention is not an independent predictor of adverse outcomes. , 2005, Circulation.

[19]  Deepak L. Bhatt,et al.  Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Periprocedural cardiac enzyme elevation predicts adverse outcomes. , 2005, Circulation.

[20]  C. Macaya,et al.  Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. , 2005, Diabetes.

[21]  J. Ioannidis,et al.  Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. , 2003, Journal of the American College of Cardiology.

[22]  R. Nesto,et al.  The platelet in diabetes: focus on prevention of ischemic events. , 2003, Diabetes care.

[23]  R. Califf,et al.  Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention , 1999 .

[24]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[25]  David P Miller,et al.  Long-term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin β3 Blockade With Percutaneous Coronary Intervention , 1997 .

[26]  David P Miller,et al.  Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. , 1997, JAMA.

[27]  R. Bonow,et al.  Prognostic implication of creatine kinase elevation following elective coronary artery interventions. , 1997, JAMA.

[28]  R. Dash,et al.  Hyperaggregation of platelets detected by whole blood platelet aggregometry in newly diagnosed noninsulin-dependent diabetes mellitus. , 1993, American journal of clinical pathology.

[29]  E J Topol,et al.  Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. , 1990, Circulation.

[30]  P. Passa,et al.  Fibrinogen binding and ADP-induced aggregation in platelets from diabetic subjects. , 1981, Thrombosis research.